12/16
08:30 am
allo
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Medium
Report
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/12
08:43 am
allo
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman [Yahoo! Finance]
Medium
Report
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman [Yahoo! Finance]
12/12
08:30 am
allo
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
Medium
Report
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman
12/12
05:44 am
allo
Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - Valued at $1.16 Billion in 2024, the Industry is Forecast to Generate Revenues of $1.69 Billion by 2028 [Yahoo! Finance]
Low
Report
Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - Valued at $1.16 Billion in 2024, the Industry is Forecast to Generate Revenues of $1.69 Billion by 2028 [Yahoo! Finance]
12/2
02:49 pm
allo
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? [Yahoo! Finance]
Low
Report
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? [Yahoo! Finance]
11/19
08:30 am
allo
Allogene Therapeutics Announces Participation in December Investor Conferences
Low
Report
Allogene Therapeutics Announces Participation in December Investor Conferences
11/18
08:35 am
allo
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence [Yahoo! Finance]
Medium
Report
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence [Yahoo! Finance]
11/18
08:30 am
allo
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
High
Report
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence
11/14
06:29 pm
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "outperform" rating re-affirmed by analysts at William Blair.
Medium
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "outperform" rating re-affirmed by analysts at William Blair.
11/14
08:15 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Piper Sandler from $11.00 to $9.00. They now have an "overweight" rating on the stock.
High
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at Piper Sandler from $11.00 to $9.00. They now have an "overweight" rating on the stock.
11/8
12:31 pm
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Low
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
11/8
11:57 am
allo
Allogene's Q3 Loss Narrower Than Expected, Sales Nil [Yahoo! Finance]
Low
Report
Allogene's Q3 Loss Narrower Than Expected, Sales Nil [Yahoo! Finance]
11/8
06:19 am
allo
Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ... [Yahoo! Finance]
High
Report
Allogene Therapeutics Inc (ALLO) Q3 2024 Earnings Call Highlights: Financial Resilience Amidst ... [Yahoo! Finance]
11/7
04:18 pm
allo
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update [Yahoo! Finance]
Medium
Report
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update [Yahoo! Finance]
11/7
04:02 pm
allo
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
Medium
Report
Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update
11/7
10:00 am
allo
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
Low
Report
Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS
11/6
07:41 am
allo
Allogene Therapeutics Inc (ALLO) Q3 2024: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
Medium
Report
Allogene Therapeutics Inc (ALLO) Q3 2024: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
11/5
09:10 am
allo
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy
Low
Report
Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy
11/4
08:30 am
allo
Allogene Therapeutics Announces Participation in November Investor Conferences
High
Report
Allogene Therapeutics Announces Participation in November Investor Conferences
10/30
09:25 am
allo
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Medium
Report
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
10/30
08:30 am
allo
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
Medium
Report
Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update
10/29
08:30 am
allo
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
Low
Report
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)
9/30
08:30 am
allo
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
Low
Report
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
9/26
08:30 am
allo
Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
Low
Report
Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence